Redeye Members Network

To access members-only content, you must login or register an account. The Redeye membership is free, but you need to apply via our application form.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

NEXT GENERATION INVESTMENT BANKING

  • Peers

Catalyst Potential

It is important to look beyond the numbers and seek a likely catalysts, which could unlock value, and estimate how long it will take for the catalyst to play out. These events, or Catalyst Potential, reduce risk by narrowing the gap between price and value in a more predictable way. This is particularly important when investing in a low-quality business where time is like a ticking bomb stacked against the company.

Catalyst Potential is a Premium members feature in Redeye Universe.

APPLY FOR MEMBERSHIP

Redeye Rating

Klas Palin

Equity Analyst

klas.palin@redeye.se

+46854501344

Company Quality

  • 7.0
  • 6.0
  • 5.5
  • 0.0
  • 1.0

Leadership

Exclusive for members
Bolaget har en kunnig och erfaren ledningsgrupp, som höjer sig över genomsnittet i branschen. VD har en god insyn i konkurrensen inom jonkanalsområdet och bör kunna driva strategiska frågor med kraft, inte minst med stöd från den omfattande erfarenheten hos styrelsen. Stort delägande och integrietet i ersättningsfrågor hos både ledning och styrelse är andra plusposter.

Ownership

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Profit outlook

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Profitability

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Capital Strength

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Key Model Assumptions - The Bear Case

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Key Model Assumptions - The Bull Case

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Key Model Assumptions - The Base Case

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Latest price

Exclusive for members

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Fair Value Range

Last Price
Key Model Assumptions - The Bear Case
Key Model Assumptions - The Bull Case
Key Model Assumptions - The Base Case

Catalyst Potential

Impact

Timeframe

Short
Mid
Long

Company description

Saniona är ett utvecklings- och forskningsbolag vars läkemedelsutveckling huvudsakligen bedrivs på tre sätt: Främst genom samarbete med större läkemedelsbolag, genom egen läkemedelsutveckling samt genom så kallade joint ventures, vilket kortfattat innebär att företag går samman och bildar ett nytt bolag för att utveckla gemensamma projekt.Till denna bild kan läggas att bolaget äger en teknikplattform som har möjlighet att fortsätta att leverera nya substanser till de ovanstående delarna.
Saniona bildades under 2011, då med namnet Aniona ApS, som ett resultat av det danska bolaget Neurosearchs beslut att avveckla alla tidiga forskningsprojekt och fokuera på ett fas III-projekt. Read more...
Saniona är ett utvecklings- och forskningsbolag vars läkemedelsutveckling huvudsakligen bedrivs på tre sätt: Främst genom samarbete med större läkemedelsbolag, genom egen läkemedelsutveckling samt genom så kallade joint ventures, vilket kortfattat innebär att företag går samman och bildar ett nytt bolag för att utveckla gemensamma projekt.Till denna bild kan läggas att bolaget äger en teknikplattform som har möjlighet att fortsätta att leverera nya substanser till de ovanstående delarna.
Saniona bildades under 2011, då med namnet Aniona ApS, som ett resultat av det danska bolaget Neurosearchs beslut att avveckla alla tidiga forskningsprojekt och fokuera på ett fas III-projekt. Under 2012 övertog Aniona de tillgångar från Neurosearch som i dagsläget utgör bolaget. Nyligen skedde en andra affär med Neurosearch där Saniona tog över rättigheterna till tesofensine. I den första affären ingick även den teknologiplattform inom jonkanalsforskning som Neurosearch byggde upp under 2000-talet. Bolaget angav i senaste delårsrapporten att antalet anställda på bolaget uppgick till 16.
Less...

TODAY

Day High
45.90
45.50
0.40
-0.9%
Day Low
44.80
Day Open
46.40
Prev Close
45.10
VWAP
45.5
Volume
13K
Turnover
0.572M
Top Broker
NON
VWAP
44.1
Avg Volume
94K
Avg Turnover
4.124M
Top Brokers
NON/AVA

52 WEEK SUMMARY

Price Range
Beta
n/a
Market Cap
956.6M
Total Return
96.6%
Trailing P/E
-26.8
Div Yield
0.0%
Shares Outstanding
20.8M
Next Earnings Date
23 May
Stock Exchange
First North Stockholm

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Rel Price Chg 3 Months 4.7%
Rel Price Chg 12 Months 67.3%
Volume Trend
Avg Vol 10 vs 60 Days 83.8%
Price vs...
52-Week High -13.7%
50-Day Moving Average 12.3%
200-Day Moving Average 18.8%

Historic pricing of Saniona

Last price: 45.50 SEK

Loading data...

Prev Close [[ prevClose|number:2 ]] SEK Change [[ changeValue|number:2 ]] %
High [[ highValue|number:2 ]] SEK Avg Daily Volume [[ avgVolume|number:0 ]] Shares
Low [[ lowValue|number:2 ]] SEK Avg Daily Turnover [[ graphAvgTurnover|number:2 ]] SEK

Management

Jørgen Drejer, CEO
Thomas Feldthus, CFO

Executive Board

Claes Braestrup, Chairman of the board
Leif Andersson
Jørgen Drejer
Carl Johan Sundberg

Last updated: 2017-03-20 Source: Redeye

Major Holders

Owner Equity Votes
Jørgen Drejer 11.4%
11.4%
Thomas Feldthus 9.0%
9.0%
Avanza Pension 5.9%
5.9%
Palle Christophersen 3.9%
3.9%
Claus Brästrup 3.5%
3.5%
Nordnet Pensionsförsäkring 3.1%
3.1%
Janus Schreiber Larsen 2.1%
2.1%
Jörgen Philip Kiär Ahring 1.9%
1.9%
Karin Sandager Nielsen 1.7%
1.7%
Jörgen Buus Lassen 1.3%
1.3%

Last updated: 2017-03-20 Source: Redeye

Insider transaction summary

Total insider purchases and sales reported

Timeframe Transactions Net Shares
Last 12 Weeks

0 Purchases

+ 0

0 Sales

- 0

Last 24 Weeks

0 Purchases

+ 0

0 Sales

- 0

Most recent insider transactions

Exclusive for members
Report Date Name Position Transaction Shares Chg Est Value (SEK)
2015-12-15 Svensson, Kim ANB Sale + 61 12
2015-12-15 Kvist, Malin ANB Sale + 74 40
2015-12-15 Kvist, Sture ANB Sale + 10 40
2015-12-15 Svensson, Kim ANB Sale + 55 93
2015-12-15 Kvist, Kim ANB Sale + 87 159

Source: Millistream – FI

More
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt (SEKm)
  • Capital employed (SEKm)
  • Capital turnover rate
Previous year Next year
2014
  • 0.0%
  • -280.9%
  • 151.7%
  • -34.8%
  • -38.0%
  • -25.0%
  • -0.39
  • -0.39
  • 0.00
  • -0.70
  • 13.9M
  • 622.0
  • -116.2
  • -116.2
  • 29.1
  • 28.6
  • -82.3
  • -75.3
  • 71.9
  • 56.8%
  • 0.0%
  • -10
  • -1
  • 1.4
2015
  • -74.4%
  • -91.0%
  • 2,422.4%
  • -200.4%
  • -206.0%
  • -168.4%
  • -1.10
  • -1.10
  • 0.00
  • -2.26
  • 20.8M
  • 901.3
  • -41.3
  • -41.3
  • 69.6
  • 66.1
  • -33.0
  • -32.1
  • 17.9
  • 91.8%
  • 0.0%
  • -47
  • 6
  • 0.2
2016E
  • 5.1%
  • 7.9%
  • 55.2%
  • 6.1%
  • 6.1%
  • 3.9%
  • 0.13
  • 0.13
  • 0.00
  • -3.27
  • 20.8M
  • 880.2
  • 342.6
  • 342.6
  • 13.9
  • 12.5
  • 205.6
  • 205.6
  • 17.5
  • 73.9%
  • 0.0%
  • -68
  • -12
  • 0.9
2017E
  • -53.5%
  • -51.9%
  • 190.4%
  • -51.2%
  • -51.8%
  • -53.4%
  • -1.13
  • -1.13
  • 0.00
  • -1.25
  • 20.8M
  • 922.1
  • -40.3
  • -40.3
  • 21.5
  • 20.9
  • -40.9
  • -40.5
  • 29.5
  • 86.9%
  • 0.0%
  • -26
  • 6
  • 1.2
2018E
  • 44.1%
  • 55.1%
  • 301.1%
  • 22.0%
  • 21.8%
  • 17.4%
  • 0.87
  • 0.87
  • 0.00
  • -3.23
  • 20.8M
  • 881.0
  • 52.1
  • 52.1
  • 9.1
  • 8.4
  • 38.3
  • 38.7
  • 18.8
  • 61.6%
  • 0.0%
  • -67
  • -17
  • 1.3
2019E
  • -63.1%
  • -80.9%
  • 143.8%
  • -67.7%
  • -68.9%
  • -53.7%
  • -1.16
  • -1.16
  • 0.00
  • -0.53
  • 20.8M
  • 937.3
  • -39.2
  • -39.2
  • 21.1
  • 20.8
  • -30.8
  • -30.2
  • 36.2
  • 100.0%
  • 0.0%
  • -11
  • 15
  • 1.7
Previous year Next year
    (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
Previous year Next year
2014
  • 22
  • -29
  • -8
  • -1
  • 0
  • 0
  • -8
  • 0
  • 1
  • 0
  • -8
  • 2
  • -5
2015
  • 14
  • -41
  • -27
  • -1
  • 0
  • 0
  • -28
  • 0
  • -1
  • 0
  • -29
  • 6
  • -23
2016E
  • 5
  • 1
  • 9
  • 5
  • 9
  • 2
  • 0
  • 3
  • 1
  • 10
  • 0
  • 1
  • 2
Q1
  • 16
  • -17
  • -1
  • -0
  • 0
  • 0
  • -1
  • 0
  • -1
  • 0
  • -2
  • -1
  • -2
Q2
  • 3
  • -16
  • -13
  • -0
  • 0
  • 0
  • -14
  • 0
  • 1
  • 0
  • -13
  • 2
  • -10
Q3E
  • 9
  • 5
  • 7
  • 4
  • 0
  • 10
  • 9
  • 3
  • 2
  • 4
  • 8
  • 5
  • 1
Q4E
  • 0
  • 3
  • 3
  • 1
  • 5
  • 1
  • 5
  • 6
  • 10
  • 1
  • 5
  • 4
  • 9
2016E
  • 4
  • 0
  • 8
  • 10
  • 10
  • 0
  • 6
  • 3
  • 3
  • 1
  • 5
  • 6
  • 1
2017E
  • 4
  • 8
  • 5
  • 2
  • 6
  • 10
  • 5
  • 4
  • 0
  • 6
  • 6
  • 8
  • 3
Q1E
  • 0
  • 9
  • 4
  • 6
  • 1
  • 2
  • 8
  • 1
  • 10
  • 5
  • 4
  • 7
  • 9
Q2E
  • 9
  • 9
  • 1
  • 7
  • 10
  • 7
  • 8
  • 0
  • 5
  • 6
  • 10
  • 10
  • 1
Q3E
  • 6
  • 1
  • 4
  • 8
  • 7
  • 2
  • 8
  • 2
  • 7
  • 6
  • 5
  • 4
  • 3
Q4E
  • 0
  • 2
  • 0
  • 0
  • 0
  • 3
  • 2
  • 9
  • 7
  • 6
  • 3
  • 8
  • 4
2017E
  • 2
  • 6
  • 8
  • 8
  • 9
  • 7
  • 10
  • 7
  • 0
  • 1
  • 5
  • 2
  • 0
2018E
  • 0
  • 8
  • 1
  • 1
  • 8
  • 5
  • 7
  • 5
  • 9
  • 3
  • 5
  • 0
  • 10
2019E
  • 4
  • 8
  • 9
  • 4
  • 3
  • 0
  • 5
  • 1
  • 2
  • 7
  • 7
  • 2
  • 3
Previous year Next year
    (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
Previous year Next year
2014
  • 10
  • 1
  • 0
  • 1
  • 11
  • 1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 1
  • 2
  • 2
  • 15
  • 0
  • 4
  • 3
  • 7
  • 0
  • 0
  • 0
  • 7
  • 0
  • 0
  • 9
  • 0
  • 9
  • 15
2015
  • 47
  • 0
  • 0
  • 2
  • 49
  • 1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2
  • 2
  • 6
  • 58
  • 0
  • 5
  • 0
  • 5
  • 0
  • 0
  • 0
  • 5
  • 0
  • 0
  • 53
  • 0
  • 53
  • 58
2016E
  • 0
  • 10
  • 10
  • 8
  • 1
  • 7
  • 10
  • 7
  • 1
  • 0
  • 7
  • 1
  • 10
  • 8
  • 4
  • 5
  • 5
  • 0
  • 7
  • 5
  • 3
  • 10
  • 6
  • 7
  • 10
  • 7
  • 2
  • 1
  • 9
2017E
  • 10
  • 5
  • 10
  • 4
  • 6
  • 10
  • 9
  • 2
  • 5
  • 1
  • 1
  • 10
  • 6
  • 3
  • 1
  • 6
  • 4
  • 4
  • 0
  • 3
  • 5
  • 7
  • 6
  • 4
  • 2
  • 4
  • 7
  • 8
  • 9
2018E
  • 0
  • 4
  • 6
  • 4
  • 4
  • 5
  • 7
  • 9
  • 2
  • 3
  • 1
  • 2
  • 9
  • 5
  • 2
  • 4
  • 3
  • 10
  • 0
  • 3
  • 3
  • 10
  • 6
  • 6
  • 4
  • 3
  • 8
  • 6
  • 10
2019E
  • 6
  • 5
  • 7
  • 6
  • 4
  • 7
  • 6
  • 7
  • 0
  • 9
  • 9
  • 6
  • 0
  • 8
  • 8
  • 6
  • 9
  • 3
  • 9
  • 3
  • 2
  • 2
  • 1
  • 10
  • 7
  • 9
  • 8
  • 1
  • 10
Previous year Next year
    (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
Previous year Next year
2014
  • 22
  • -29
  • -1
  • -8
  • 2
  • -6
  • 1
  • -5
  • 2
  • -1
  • -5
2015
  • 14
  • -41
  • -1
  • -28
  • 6
  • -22
  • 1
  • -21
  • -9
  • -1
  • -9
2016E
  • 9
  • 6
  • 2
  • 1
  • 5
  • 5
  • 7
  • 4
  • 2
  • 3
  • 0
2017E
  • 4
  • 2
  • 7
  • 1
  • 3
  • 0
  • 0
  • 5
  • 1
  • 6
  • 3
2018E
  • 10
  • 5
  • 2
  • 3
  • 8
  • 9
  • 7
  • 7
  • 5
  • 8
  • 5
2019E
  • 8
  • 0
  • 2
  • 2
  • 9
  • 10
  • 6
  • 10
  • 4
  • 7
  • 6
Previous year Next year
More